Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,727 active trials51 approved drugs619 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,611 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00589056 | Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 55 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 24, 2020 | clinicaltrials |
| NCT02336451 | A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges(Ascend-7) | completed | Phase 2 | 156 | Novartis PharmaceuticalsINDUSTRY |
| 17 |
| Apr 21, 2020 |
| clinicaltrials |
| NCT03499834 | A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy(IVY03) | completed | Phase 2 | 26 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02573506 | Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer | completed | Phase 2 | 99 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT01466660 | LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | completed | Phase 2 | 319 | Boehringer IngelheimINDUSTRY | 14 | Apr 7, 2020 | clinicaltrials |
| NCT00006229 | Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 774 | NCIC Clinical Trials GroupNETWORK | 14 | Apr 6, 2020 | clinicaltrials |
| NCT00137800 | Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01773109 | Etirinotecan Pegol (NKTR-102) in NSCLC | completed | Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00436332 | S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma | completed | Phase 2 | 84 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 2, 2020 | clinicaltrials |
| NCT00489008 | SRS Study in Patients With Non-Small Cell Lung Cancer | completed | Phase 2 | 141 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 30, 2020 | clinicaltrials |
| NCT01876446 | Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 38 | Roswell Park Cancer InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT02735980 | A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer | completed | Phase 2 | 133 | Eli Lilly and CompanyINDUSTRY | 10 | Mar 17, 2020 | clinicaltrials |
| NCT00792701 | S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer | completed | Phase 2 | 85 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2020 | clinicaltrials |
| NCT00445848 | S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 89 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00514215 | Cryotherapy and GM-CSF in Treating Patients With Lung Metastases or Primary Lung Cancer | completed | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT00960999 | Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer | completed | Phase 2 | 94 | Radiation Therapy Oncology GroupNETWORK | 2 | Mar 4, 2020 | clinicaltrials |
| NCT02544633 | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | completed | Phase 2 | 68 | Mirati Therapeutics Inc.INDUSTRY | 9 | Mar 4, 2020 | clinicaltrials |
| NCT00661193 | S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 59 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT03652857 | Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer | completed | Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00227708 | Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 2 | 58 | UNICANCEROTHER | 3 | Feb 13, 2020 | clinicaltrials |
| NCT02590965 | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 91 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT00613626 | Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 74 | Hoosier Cancer Research NetworkOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT02551432 | Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer(MISP-MK3475) | completed | Phase 2 | 26 | Seoul National University HospitalOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT03155009 | A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer(ATALK) | completed | Phase 2 | 44 | Hoffmann-La RocheINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01933347 | Third-line Treatment of Gefitinib in NSCLC Patients | completed | Phase 2 | 46 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT00411632 | BATTLE Program: Tarceva and Targretin in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 29, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01310244 | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 23 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH) | completed | Phase 2 | 667 | Hoffmann-La RocheINDUSTRY | 19 | Jan 6, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT01880528 | Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer | completed | Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00200395 | OSI-774 (Erlotinib, Tarceva) in Elderly Patients | completed | Phase 2 | 30 | Montefiore Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT00978250 | A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine (FdCyd + THU) | completed | Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Dec 27, 2019 | clinicaltrials |
| NCT02047344 | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | completed | Phase 2 | 31 | Golden Biotechnology CorporationINDUSTRY | 2 | Dec 26, 2019 | clinicaltrials |
| NCT01813734 | Ponatinib in Advanced NSCLC w/ RET Translocations | completed | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Dec 24, 2019 | clinicaltrials |
| NCT00137839 | Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | completed | Phase 2 | 84 | Pasi A. Janne, MD, PhDOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00064012 | Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT00798720 | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 0 | Dec 13, 2019 | clinicaltrials |
| NCT03129256 | An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer(EASE) | completed | Phase 2 | 52 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00563784 | TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00388960 | Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer | completed | Phase 2 | 99 | CelgeneINDUSTRY | 5 | Nov 19, 2019 | clinicaltrials |
| NCT00582634 | Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer | completed | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02976116 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 50 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00274443 | An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin | completed | Phase 2 | 250 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00617409 | To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid | completed | Phase 2 | 69 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01631357 | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer(CIK) | completed | Phase 2 / Phase 3 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT00771953 | 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer | completed | Phase 2 | 109 | University of Maryland, BaltimoreOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00894127 | Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer | completed | Phase 1 / Phase 2 | 128 | Biomoda Inc.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Apr 24, 2020source: clinicaltrials